Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma

Advanced cancer of the stomach and the gastro-esophageal junction (G/GEJ) remains a very serious disease. Today, only about 10-15% of patients are alive after 5 years. Treatments mainly aim to control symptoms, extend life, and maintain quality of life. First treatments usually combine two chemotherapies, but recent years have brought real progress. Immunotherapy - drugs that "unlock" the immune system - has shown clear benefits. For patients whose tumors have certain markers (like PD-L1), combining drugs such as nivolumab or pembrolizumab with chemotherapy can help patients live longer. Anot

Trial Details

NCT ID
NCT07270991
Phase
PHASE3
Sponsor
Federation Francophone de Cancerologie Digestive
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • trifluridine/tipiracil
  • fruquintinib
Locations (sample)
  • Aurillac, France|44.92539,2.43983
  • Avignon, France|43.94834,4.80892
  • Bayeux, France|49.27732,-0.7039
  • Bayonne, France|43.49316,-1.473
  • Bezannes, France|49.22339,3.98892

Key Eligibility Criteria

  • Age ≥ 18 years (patients enrolled gender independently).
  • Histologically proven metastatic adenocarcinoma of the stomach or the esophagogastric junction (GEJ) or esophagus.
  • Prior treatment by two or three lines of treatment for metastatic setting (patients who received adjuvant therapy and developed metastatic disease …
  • Prior treatment (progression or intolerance) with platinum salts (oxaliplatin or cisplatin), fluoropyrimidine and irinotecan and/or taxane (+/- ant…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →